Literature DB >> 17502350

Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.

Bin Shi1, Jing Liang, Xiaohan Yang, Yan Wang, Youna Zhao, Huijian Wu, Luyang Sun, Ying Zhang, Yupeng Chen, Ruifang Li, Yu Zhang, Mei Hong, Yongfeng Shang.   

Abstract

Essential for embryonic development, the polycomb group protein enhancer of zeste homolog 2 (EZH2) is overexpressed in breast and prostate cancers and is implicated in the growth and aggression of the tumors. The tumorigenic mechanism underlying EZH2 overexpression is largely unknown. It is believed that EZH2 exerts its biological activity as a transcription repressor. However, we report here that EZH2 functions in gene transcriptional activation in breast cancer cells. We show that EZH2 transactivates genes that are commonly targeted by estrogen and Wnt signaling pathways. We demonstrated that EZH2 physically interacts directly with estrogen receptor alpha and beta-catenin, thus connecting the estrogen and Wnt signaling circuitries, functionally enhances gene transactivation by estrogen and Wnt pathways, and phenotypically promotes cell cycle progression. In addition, we identified the transactivation activity of EZH2 in its two N-terminal domains and demonstrated that these structures serve as platforms to connect transcription factors and the Mediator complex. Our experiments indicated that EZH2 is a dual function transcription regulator with a dynamic activity, and we provide a mechanism for EZH2 in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502350      PMCID: PMC1951944          DOI: 10.1128/MCB.00162-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  60 in total

1.  The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.

Authors:  H P Visser; M J Gunster; H C Kluin-Nelemans; E M Manders; F M Raaphorst; C J Meijer; R Willemze; A P Otte
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

Review 2.  Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.

Authors:  Yongfeng Shang
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

Review 3.  The diverse functions of histone lysine methylation.

Authors:  Cyrus Martin; Yi Zhang
Journal:  Nat Rev Mol Cell Biol       Date:  2005-11       Impact factor: 94.444

Review 4.  Steroid hormone receptor signaling in tumorigenesis.

Authors:  Rajesh R Singh; Rakesh Kumar
Journal:  J Cell Biochem       Date:  2005-10-15       Impact factor: 4.429

5.  Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription.

Authors:  Y Shang; X Hu; J DiRenzo; M A Lazar; M Brown
Journal:  Cell       Date:  2000-12-08       Impact factor: 41.582

6.  Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation.

Authors:  Huijian Wu; Luyang Sun; Ying Zhang; Yupeng Chen; Bin Shi; Ruifang Li; Yan Wang; Jing Liang; Dongwei Fan; Ge Wu; Dan Wang; Shaosi Li; Yongfeng Shang
Journal:  J Biol Chem       Date:  2006-06-07       Impact factor: 5.157

7.  Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis.

Authors:  Huijian Wu; Yupeng Chen; Jing Liang; Bin Shi; Ge Wu; Ying Zhang; Dan Wang; Ruifang Li; Xia Yi; Hua Zhang; Luyang Sun; Yongfeng Shang
Journal:  Nature       Date:  2005-12-15       Impact factor: 49.962

8.  Dynein light chain 1 contributes to cell cycle progression by increasing cyclin-dependent kinase 2 activity in estrogen-stimulated cells.

Authors:  Petra den Hollander; Rakesh Kumar
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

9.  Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc.

Authors:  Vanessa Rodrik; Yang Zheng; Faith Harrow; Yuhong Chen; David A Foster
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

Review 10.  Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.

Authors:  Anupama E Gururaj; Suresh K Rayala; Ratna K Vadlamudi; Rakesh Kumar
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

View more
  160 in total

1.  ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.

Authors:  Hua Li; Benjamin G Bitler; Vinod Vathipadiekal; Marie E Maradeo; Michael Slifker; Caretha L Creasy; Peter J Tummino; Paul Cairns; Michael J Birrer; Rugang Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-05

2.  Corepressor protein CDYL functions as a molecular bridge between polycomb repressor complex 2 and repressive chromatin mark trimethylated histone lysine 27.

Authors:  Yu Zhang; Xiaohan Yang; Bin Gui; Guojia Xie; Di Zhang; Yongfeng Shang; Jing Liang
Journal:  J Biol Chem       Date:  2011-10-17       Impact factor: 5.157

3.  ATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Xiaodong Sun; Peng Guo; Qunna Li; Masakiyo Sasahara; Yoko Ishii; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

4.  Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2.

Authors:  Meilan He; Wei Zhang; Thomas Bakken; Melissa Schutten; Zsolt Toth; Jae U Jung; Parkash Gill; Mark Cannon; Shou-Jiang Gao
Journal:  Cancer Res       Date:  2012-05-16       Impact factor: 12.701

5.  JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 regulation.

Authors:  Luyang Sun; Lei Shi; Wenqian Li; Wenhua Yu; Jing Liang; Hua Zhang; Xiaohan Yang; Yan Wang; Ruifang Li; Xingrong Yao; Xia Yi; Yongfeng Shang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-09       Impact factor: 11.205

6.  The polycomb protein Ezh2 impacts on induced pluripotent stem cell generation.

Authors:  Xiaolei Ding; Xiaoying Wang; Stephanie Sontag; Jie Qin; Paul Wanek; Qiong Lin; Martin Zenke
Journal:  Stem Cells Dev       Date:  2014-01-21       Impact factor: 3.272

Review 7.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

8.  PAF makes it EZ(H2) for β-catenin transactivation.

Authors:  Xinjun Zhang; Xi He
Journal:  Mol Cell       Date:  2013-10-24       Impact factor: 17.970

9.  STAT3-driven transcription depends upon the dimethylation of K49 by EZH2.

Authors:  Maupali Dasgupta; Josephine Kam Tai Dermawan; Belinda Willard; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-12       Impact factor: 11.205

10.  EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.

Authors:  Heather M Moore; Maria E Gonzalez; Kathy A Toy; Ashley Cimino-Mathews; Pedram Argani; Celina G Kleer
Journal:  Breast Cancer Res Treat       Date:  2013-03-29       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.